View Item 

Show simple item record

Treatment of allergic disease with nanoemulsion adjuvant vaccines
dc.contributor.authorO’konek, Jessica J.
dc.contributor.authorBaker, James R.
dc.date.accessioned2020-01-13T15:21:04Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-01-13T15:21:04Z
dc.date.issued2020-01
dc.identifier.citationO’konek, Jessica J. ; Baker, James R. (2020). "Treatment of allergic disease with nanoemulsion adjuvant vaccines." Allergy 75(1): 246-249.
dc.identifier.issn0105-4538
dc.identifier.issn1398-9995
dc.identifier.urihttps://hdl.handle.net/2027.42/153245
dc.publisherWiley Periodicals, Inc.
dc.titleTreatment of allergic disease with nanoemulsion adjuvant vaccines
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153245/1/all13977_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/153245/2/all13977.pdf
dc.identifier.doi10.1111/all.13977
dc.identifier.sourceAllergy
dc.identifier.citedreferenceBaker JR Jr, Bielinska AU, Smith D, Makidon PE, O’Konek JJ. Inventor. Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease. Patent WO 2016/057921A1, EP 3204039A4, JP 2017/534608A, US 2017/0246294 A12.
dc.identifier.citedreferenceWong PT, Leroueil PR, Smith DM, et al. Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsionâ based intranasal vaccine adjuvants. PLoS ONE. 2015; 10 ( 5 ): e0126120.
dc.identifier.citedreferenceO’Konek JJ, Landers JJ, Janczak KW, et al. Nanoemulsion adjuvantâ driven redirection of TH2 immunity inhibits allergic reactions in murine models of peanut allergy. J Allergy Clin Immunol. 2018; 141 ( 6 ): 2121 â 2131.
dc.identifier.citedreferenceHinz D, Seumois G, Gholami AM, et al. Lack of allergy to timothy grass pollen is not a passive phenomenon but associated with the allergenâ specific modulation of immune reactivity. Clin Exp Allergy. 2016; 46 ( 5 ): 705 â 719.
dc.identifier.citedreferenceSchulten V, Tripple V, Sidney J, et al. Association between specific timothy grass antigens and changes in TH1â and TH2â cell responses following specific immunotherapy. J Allergy Clin Immunol. 2014; 134 ( 5 ): 1076 â 1083.
dc.identifier.citedreferenceMakidon PE, Bielinska AU, Nigavekar SS, et al. Preâ clinical evaluation of a novel nanoemulsionâ based hepatitis B mucosal vaccine. PLoS ONE. 2008; 3 ( 8 ): e2954.
dc.identifier.citedreferenceHamouda T, Sutcliffe JA, Ciotti S, Baker JR Jr. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsionâ based adjuvant. Clin Vaccine Immunol. 2011; 18 ( 7 ): 1167 â 1175.
dc.identifier.citedreferenceBielinska AU, Makidon PE, Janczak KW, et al. Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. J Immunol. 2014; 192 ( 6 ): 2722 â 2733.
dc.identifier.citedreferenceStanberry LR, Simon JK, Johnson C, et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine. 2012; 30 ( 2 ): 307 â 316.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
all13977_am.pdf
Size:
198.0KB
Format:
PDF
View/Open
Name:
all13977.pdf
Size:
578.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.